Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Ascorbic Acid (HDAA) in Relapsed Refractory Multiple Myeloma
NCT06313502Phase 1Recruiting
- Sponsor
- University of Arkansas
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ascorbic acid in multiple myeloma (MM) (3 arms), sponsored by University of Arkansas. Primary endpoint: Tumor Response at 24 months. Started Jul 2024; status: recruiting.
02
Drugs
ascorbic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06313502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313502.